Showing results (31-40 of 139) with videos related to

Sort By:
Pageof 14
Annals of Surgical Oncology|June 27, 2008
Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapyThomas Yau, C Y Lo, R J Epstein, et al.
The Oncologist|September 3, 2011
The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenibThomas Yau, T J Yao, Pierre Chan, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|January 1, 2014
Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysisJoanne Chiu, Vikki Tang, Roland Leung, et al.
Postgraduate Medical Journal|November 13, 2016
The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong KongKa-On Lam, Kin-Chung Lee, Joanne Chiu, et al.
The Oncologist|August 14, 2014
Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapyJoanne W Chiu, Hilda Wong, Roland Leung, et al.
Gastroenterology|March 4, 2014
Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinomaThomas Yau, Vikki Y F Tang, Tzy-Jyun Yao, et al.
Cancer|December 25, 2008
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor responseThomas Yau, Pierre Chan, Kelvin K Ng, et al.
Cell Reports. Medicine|September 26, 2025
Phocaeicola vulgatus induces immunotherapy resistance in hepatocellular carcinoma via reducing indoleacetic acid productionCai-Ning Zhao, Shan-Shan Li, Thomas Yau, et al.
Investigational New Drugs|March 10, 2012
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory diseaseThomas Yau, Hilda Wong, Pierre Chan, et al.
Anti-Cancer Agents in Medicinal Chemistry|October 25, 2012
Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapyRoland Leung, Brian Lang, Hilda Wong, et al.
Pageof 14